Articles tagged with Lung Cancer
Patients with recurrent lung cancer who undergo a CT-based follow-up program after surgery experience significantly improved post-surgery survival rates. The study analyzed 391 patients and found that the number of patients alive four years after surgery increased from 54% to an estimated 68%.
Researchers discovered genetic changes in premalignant lung lesions that occurred before cancerous growth, detectable in blood samples. The findings suggest that circulating DNA can be used to identify patients at risk of developing lung cancer, enabling early intervention and potentially improving treatment outcomes.
According to a comprehensive report by the American Cancer Society, cancer is the second leading cause of death overall in the US, but it remains the leading cause of death among US Hispanics. Lung cancer is the primary concern, particularly for Hispanic men, who are more likely to die from this disease.
A multidisciplinary team is designing a mathematical model for autophagy in lung cancer to develop novel cancer treatment strategies. The model will be used to systematically evaluate therapeutic strategies and identify the most promising ones, which can then be evaluated experimentally.
A University of Colorado Cancer Center study found that 41% of open lung cancer clinical trials excluded patients with previously treated CNS disease, while 26% allowed those with untreated CNS involvement. The study suggests that current practice may be based on habit rather than scientific rationale.
A CTCA study found that the lung microbiome diversity in patients with lung cancer was characterized by a significant presence of Streptococcaceae family bacteria. This discovery may lead to new pharmacological cancer prevention strategies and improved treatment outcomes for lung cancer patients.
A University of Colorado Cancer Center study identified a specific ratio of MET to centromere 7 that defines patients with MET-driven lung cancer susceptible to crizotinib treatment. This threshold has been associated with responses approaching 70 percent in clinical trials.
The International Association for the Study of Lung Cancer has released new data for the TNM classification of lung cancer, which will inform the Eighth Edition of the staging manual. The new database includes 94,708 patients diagnosed worldwide from 1999-2010 and analyzes tumor size, lymph node involvement, and metastatic status.
The new 2015 WHO Classification of Lung Tumors provides standard criteria for pathology diagnosis and clinical practice. The updated classification focuses on histologic subtyping and classification according to predominant subtype, leading to multiple new discoveries in lung adenocarcinoma.
The International Association for the Study of Lung Cancer (IASLC) has issued a new statement on tobacco control and smoking cessation, calling for increased taxes on tobacco products to reduce cigarette smoking. The organization also emphasizes comprehensive advertising and promotion bans and product regulation, including pack warnings.
Men in China face increasing tobacco-related cancer risks due to high cigarette smoking rates among teenagers and continued use in adulthood. The country now produces and consumes nearly 40% of the world's cigarettes, primarily driven by men's smoking habits.
A study by UC Davis researchers has identified two biomarkers that can detect lung cancer up to six months before diagnosis, with an 80% accuracy rate. The findings offer a promising alternative to expensive low-dose CT scans, which involve X-ray radiation.
A nine-gene molecular prognostic index (MPI) provides accurate survival stratification for early-stage non-small cell lung cancer (NSCLC) patients. The MPI combines gene expression profiles with clinical data from a large database, enabling robust and clinically applicable predictions.
The International Association for the Study of Lung Cancer (IASLC) has selected 5 advocates to attend the 16th World Conference on Lung Cancer, where they will share and learn strategies to increase awareness. The recipients include Hildreth Grossman, Kathleen Mewhiney, Victor Lasebikan, Seda Kansu, and Tetsuya Yamaoka.
A recent study published in The Annals of Thoracic Surgery found that patients with suspected lung cancer often wait too long to receive treatment and skip vital diagnostic steps. Only 1 in 10 patients had the recommended combination of three staging tests before surgery, highlighting the need for improved quality care.
A study found a significant association between long telomere length and increased risk of lung adenocarcinoma. Long telomeres were associated with more rounds of cell division, potentially allowing for more opportunities to accumulate carcinogenic mutations.
Researchers discovered a small RNA molecule called miR-148a plays a role in lung cancer resistance to TRAIL, and inhibiting NF-κB makes it more effective. This study suggests a way to overcome resistance and develop new treatments for lung cancer.
A comprehensive lung cancer screening program utilizing CT scan technology at Intermountain Medical Center has been developed to detect lung cancer more accurately. The program, based on the National Lung Screening Trial, showed patients with CT scans had a 15-20% lower risk of dying compared to those with standard chest X-rays.
Researchers use light therapy glasses to trigger neurotransmitters and reset sleep cycles in lung cancer patients. Studies found that 50-80% of lung cancer patients experience severe insomnia, which can persist for eight years after diagnosis.
A new study published in Radiology found that annual low-dose computed tomography (CT) screening can safely monitor people with nonsolid lung nodules, reducing the need for unnecessary surgery and additional imaging. Nonsolid nodules are visible on CT scans of the chest and management is challenging.
A new study found annual low-dose CT screening to be safe and effective for identifying pre-cancerous lung nodules. The study identified cases of cancer in participants with nonsolid lung nodules, which can progress to invasive cancer.
A new study finds that providing direct assistance, such as counseling and nicotine replacement therapy, significantly improves the likelihood of patients quitting smoking. The research team analyzed data from over 1,600 participants who underwent lung cancer screening, finding that active clinician support increased quit rates by 40%.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that lung cancer patients with comorbidities such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death. These patients also experienced poorer survival rates at each stage of the disease.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
Researchers at the Weizmann Institute have developed a three-pronged approach to prevent lung cancer cells from developing resistance to chemotherapy. The new strategy involves targeting two main growth receptor siblings, HER2 and HER3, in addition to an existing anti-EGFR antibody.
Researchers at The Wistar Institute have identified a protein biomarker AKAP4 that appears to be more accurate in detecting non-small cell lung cancer. This discovery could lead to the development of a simple blood test for annual screening, potentially saving lives by detecting the disease earlier.
The global burden of disease study estimated 14.9 million new cancer cases and 8.2 million deaths in 2013. Lung and breast cancers were the leading causes of cancer-related deaths, with tracheal bronchus and lung cancer being the most common among men.
Researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis in lung cancer treatment by inhibiting the Bcl-2 protein. A new class of compounds has been identified that bind to the BH4 domain of Bcl-2, promoting cancer cell death.
A study found that 38% of lung cancer survivors developed recurrent or new cancer during a 8.3-year surveillance period. Key risk factors for recurrence included smoking status, prior cancers, and asbestos exposure, highlighting the need for close monitoring and quitting smoking to reduce cancer recurrence.
Researchers at Johns Hopkins Medicine have designed a molecule called RK-33 to target the enzyme DDX3, which is overexpressed in over 90% of lung cancer samples. The therapy has shown promising results in mice, with the ability to lower radiation doses while increasing its effectiveness.
Researchers found that adding genetic information to a smoker's clinical risk profile results in improved lung cancer screening adherence, with higher-risk individuals more likely to adhere to follow-up CT scans. The study suggests that gene-based risk assessment can improve screening compliance and reduce the need for reclassification.
A new genomic test has been validated for detecting lung cancer with high sensitivity, allowing physicians to identify patients at low probability of having the disease. This test can spare patients from costly and risky procedures, improving diagnosis and patient anxiety.
A phase III randomized clinical trial suggests that Stereotactic Ablative Radiotherapy (SABR) is equally effective to surgery in treating operable stage I non-small cell lung cancer patients, with better survival rates and lower toxicity. SABR appears to be a suitable alternative for elderly and comorbidity-prone patients.
Researchers from the University of Waterloo discovered a new family of nonplatinum-based halogenated molecules that selectively target cancer cells while protecting healthy cells. These molecules generate reactive radicals that kill cancer cells, and increase the protective molecule glutathione in healthy cells.
Researchers from CNIO have discovered a new approach to fighting cancer by targeting telomeres and blocking the TRF1 gene. This method shows dramatic improvements in mice with lung cancer, with minimal toxic effects, offering a promising therapeutic target for cancer therapy.
Myriad Genetics presented 19 clinical studies on advanced companion diagnostic and molecular diagnostic tests for cancer treatment and prevention. The company's research focuses on personalized medicine, including selecting effective pharmaceuticals, preventing disease through hereditary cancer tests, and optimizing treatment decisions...
Researchers found that relatives play a crucial role in encouraging loved ones to seek medical help for lung cancer, while online information poses problems. A new website is planned to provide tailored guidance for those experiencing symptoms.
Research shows that family members are more likely to search online for lung cancer information, encouraging loved ones to seek medical help. Psychologists aim to develop a website providing tailored information for those experiencing lung cancer symptoms.
Researchers at the University of Manchester have developed a new genetic profiling approach to identify patients with right lung cancer who are eligible for targeted therapies. The method uses smaller tissue biopsies and has been shown to detect genetic changes in over 95% of samples.
A phase 1/2 trial of rociletinib in EGFR-mutant non-small cell lung cancer showed a 59% response rate and 13.1 month progression-free survival, offering hope for patients with previously treated disease.
Researchers at the University of Louisville have detailed a crucial connection between silica exposure and rapid lung cancer progression, highlighting the role of inflammatory mediator LTB4 and its receptor BLT1. The study's findings suggest that novel treatment strategies for both silicosis and associated lung cancers may be possible.
A new study found that lung cancer surgery patients have a higher risk of developing venous thromboembolism (VTEs) than previously thought. The study, which analyzed data from 157 patients, showed that the incidence rate was 12.1%, with most events occurring after discharge from the hospital and without symptoms.
A study of over 8000 patients found that surgeons with higher volumes are less likely to perform high-risk pneumonectomies, leading to better long-term survival. The researchers suggest that surgeon experience is an important factor in determining surgical outcomes for non-small cell lung cancer patients.
A new analysis of the Surveillance, Epidemiology, and End Results (SEER) database found significant variation in health insurance coverage among cancer patients based on demographics and cancer type. Younger, non-White, and rural patients were more likely to be uninsured, while males were less likely than females to have insurance.
A systematic review of cigar smoking and all-cause and smoking-related mortality found that cigar smoking carries the same fatal health risks as cigarette smoking, including oral, esophageal, and lung cancers. The risk of death from these cancers increases with inhalation of cigar smoke.
Researchers at MD Anderson Cancer Center have uncovered a novel mechanism by which the tumor suppressor gene p53 regulates PD-L1, allowing non-small cell lung cancer to grow. MicroRNA delivery with existing treatments may represent a new therapeutic approach for lung cancer.
Research by University of Colorado Cancer Center investigator Tim Byers found that taking more dietary supplements than needed can lead to a higher risk of developing cancer. The study, which involved thousands of patients and ten years of research, showed that some supplements may even increase cancer risk by 20%.
Researchers have developed a new diagnostic method called spectral histopathology that facilitates marker-free detection of individual subtypes of lung cancers. The accuracy of this method is higher than traditional histopathology, reaching over 92%, allowing for more precise diagnosis and personalized treatment options.
Researchers from MD Anderson Cancer Center are part of two new Stand Up to Cancer Dream Teams focused on lung cancer driven by KRAS mutations and preventing high-risk ovarian cancer. The teams aim to test combination therapies and launch prevention efforts.
The $20 million SU2C-American Cancer Society Lung Cancer Dream Team will focus on targeting KRAS mutant lung cancer using a three-pronged approach. The team aims to develop novel therapies that combine targeted drug therapies with immunotherapies to improve patient outcomes.
Researchers at MD Anderson Cancer Center identified three subsets of lung cancer with KRAS gene mutations, each with unique signaling patterns and susceptibility to different therapeutic strategies. These subsets may offer new approaches for treating lung adenocarcinoma, the most common form of lung cancer.
A study of oncologists in Europe, Asia, and the US found that nearly one in four patients with advanced lung cancer began treatment without knowing their EGFR mutation status. This lack of testing may compromise treatment outcomes and access to effective therapies.
A survey of French people aged 40-75 found that many incorrectly believed low cigarette consumption was risk-free for lung cancer. Only half of current smokers considered themselves at higher risk than the average population.
A subset of lung cancer patients with BRAF-mutant cancers may derive significant clinical benefits from treatment with BRAF inhibitors, according to a European study. The trial found an overall response rate of 53% and progression-free survival time of 5 months among patients treated with vemurafenib or dabrafenib.
A new DNA blood test can identify EGFR mutations in lung cancer patients without accessible tumor tissue, showing an 89% agreement rate with tissue testing. The test's sensitivity was found to be around half of that of traditional tissue testing.
A recent study by the Journal of the American College of Surgeons found that socioeconomic factors such as income level, education, and hospital type significantly impact lung cancer patients' odds of death within 30 days after surgery. Patients from lower-income households were 25% more likely to die than those in higher-income areas.
A new study finds that racial disparities in cancer outcomes are decreasing, with African Americans showing faster decreases in cancer mortality than Caucasians. The causes of these disparities include low education and income, as well as reduced access to quality healthcare.
The first Heine H. Hansen Award recipient, Pieter Postmus, has made significant contributions to lung cancer research and education globally. He was recognized for his work in developing research programs in pulmonary circulation, pneumothorax, and thoracic oncology.
The study of over 160,000 postmenopausal women revealed no significant link between lung cancer risk and reproductive history or hormone therapy. However, some subgroups showed reduced risks for specific types of lung cancer, emphasizing the need for further research into complex relationships.
Researchers say there is enough evidence to declare indoor UV radiation tanning causes skin cancer. The authors urge the US Surgeon General to make a stronger statement regarding UV tanning devices, citing eight out of nine Bradford Hill criteria as satisfied.